|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herr HW: Transurethral resection of
muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol.
19:89–93. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sievert KD, Amend B, Nagele U, Schilling
D, Bedke J, Horstmann M, Hennenlotter J, Kruck S and Stenzl A:
Economic aspects of bladder cancer: What are the benefits and
costs? World J Urol. 27:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carneiro BA, Meeks JJ, Kuzel TM, Scaranti
M, Abdulkadir SA and Giles FJ: Emerging therapeutic targets in
bladder cancer. Cancer Treat Rev. 41:170–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dobruch J, Daneshmand S, Fisch M, Lotan Y,
Noon AP, Resnick MJ, Shariat SF, Zlotta AR and Boorjian SA: Gender
and bladder cancer: A collaborative review of etiology, biology,
and outcomes. Eur Urol. 69:300–310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder
cancer. Lancet. 388:2796–2810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Izumi K and Miyamoto H: The role of
the androgen receptor in the development and progression of bladder
cancer. Jpn J Clin Oncol. 42:569–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhuang YH, Bläuer M, Tammela T and
Tuohimaa P: Immunodetection of androgen receptor in human urinary
bladder cancer. Histopathology. 30:556–562. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boorjian S, Ugras S, Mongan NP, Gudas LJ,
You X, Tickoo SK and Scherr DS: Androgen receptor expression is
inversely correlated with pathologic tumor stage in bladder cancer.
Urology. 64:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boorjian SA, Heemers HV, Frank I, Farmer
SA, Schmidt LJ, Sebo TJ and Tindall DJ: Expression and significance
of androgen receptor coactivators in urothelial carcinoma of the
bladder. Endocr Relat Cancer. 16:123–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mir C, Shariat SF, van der Kwast TH,
Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C,
et al: Loss of androgen receptor expression is not associated with
pathological stage, grade, gender or outcome in bladder cancer: A
large multi-institutional study. BJU Int. 108:24–30. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. Int J Surg. 8:336–341.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Egger M, Smith Davey G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tuygun C, Kankaya D, Imamoglu A, Sertcelik
A, Zengin K, Oktay M and Sertcelik N: Sex-specific hormone
receptors in urothelial carcinomas of the human urinary bladder: A
comparative analysis of clinicopathological features and survival
outcomes according to receptor expression. Urol Oncol. 29:43–51.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng Y, Izumi K, Yao JL and Miyamoto H:
Dihydrotestosterone upregulates the expression of epidermal growth
factor receptor and ERBB2 in androgen receptor-positive bladder
cancer cells. Endocr Relat Cancer. 18:451–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu
I, Izumi K, Chang C, Messing EM, Netto GJ and Yeh S: Expression of
androgen and Oestrogen receptors and its prognostic significance in
urothelial neoplasm of the urinary bladder. BJU Int. 109:1716–1726.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mashhadi R, Pourmand G, Kosari F, Mehrsai
A, Salem S, Pourmand MR, Alatab S, Khonsari M, Heydari F, Beladi L
and Alizadeh F: Role of steroid hormone receptors in formation and
progression of bladder carcinoma: A case-control study. Urol J.
11:1968–1973. 2014.PubMed/NCBI
|
|
23
|
Nam JK, Park SW, Lee SD and Chung MK:
Prognostic value of sex-hormone receptor expression in
non-muscle-invasive bladder cancer. Yonsei Med J. 55:1214–1221.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jing Y, Cui D, Guo W, Jiang J, Jiang B, Lu
Y, Zhao W, Wang X, Jiang Q, Han B and Xia S: Activated androgen
receptor promotes bladder cancer metastasis via Slug mediated
epithelial-mesenchymal transition. Cancer Lett. 348:135–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Williams EM, Higgins JP, Sangoi AR,
McKenney JK and Troxell ML: Androgen receptor immunohistochemistry
in genitourinary neoplasms. Int Urol Nephrol. 47:81–85. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota
J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al:
Expression of androgen receptor in non-muscle-invasive bladder
cancer predicts the preventive effect of androgen deprivation
therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang CS, Kokontis J and Liao ST:
Molecular cloning of human and rat complementary DNA encoding
androgen receptors. Science. 240:324–326. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Culig Z and Santer FR: Androgen receptor
co-activators in the regulation of cellular events in prostate
cancer. World J Urol. 30:297–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lombard AP and Mudryj M: The emerging role
of the androgen receptor in bladder cancer. Endocr Relat Cancer.
22:R265–R277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang C, Lee SO, Yeh S and Chang TM:
Androgen receptor (AR) differential roles in hormone-related tumors
including prostate, bladder, kidney, lung, breast and liver.
Oncogene. 33:3225–3234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guan Z, Li C, Fan J, He D and Li L:
Androgen receptor (AR) signaling promotes RCC progression via
increased endothelial cell proliferation and recruitment by
modulating AKT→ NF-κB →CXCL5 signaling. Sci Rep. 6:370852016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miyamoto H, Yang Z, Chen YT, Ishiguro H,
Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cance Inst. 99:558–568. 2007. View Article : Google Scholar
|
|
33
|
Lopez-Beltran A and Montironi R:
Non-invasive urothelial neoplasms: According to the most recent WHO
classification. Eur Urol. 46:170–176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen C, Qi XJ, Cao YW, Wang YH, Yang XC,
Shao SX and Niu HT: Bladder tumor heterogeneity: The impact on
clinical treatment. Urol Int. 95:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A:
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
